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Abstract  
BACKGROUND: NK cells are characterized by cytotoxic activity against tumor cells and CD3-
CD16+CD56+ phenotype. Two distinct subpopulations of NK cells were characterized in the 
peripheral blood: NK-CD56
dim
 representing over 95% of NK cells and involved in antitumor 
cytotoxicity, and NK-CD56
bright
 representing approximately 10% of NK cells and involved in 
secretion of cytokines.  
AIM: The aim of the study was to compare the presence of NK-CD56
dim
/NK-CD56
bright
 
subpopulations and their CD16/CD57 expression in peripheral blood NK cells during the 
particular development stages of malignancy: primary tumor (PT), lymph node invasion (LNI) 
and distant sites metastases (Mt).  
MATERIAL AND METHODS: We have analyzed by flow-cytometry peripheral blood samples 
from total 36 cancer patients: 24 patients with PT, 6 patients with LNI and 6 patients with Mt.  
RESULTS: The presence of the overall NK cells showed no significant variation between 
patients in different stages of tumor development. The phenotype analysis showed that CD16+ 
and/or CD57+ cells were lower in LNI patients compared to PT or Mt patients. Double-positive 
CD16+CD57+ cells were found decreased in patients with Mt, compared to patients with PT. 
During the stages of tumor development, NK-CD56
bright
 subpopulation increased progressively 
(7% in PT patients, 13% in LNI patients, 65% in Mt patients), whereas NK-CD56
dim
 
subpopulation gradually decreased (92%, 86%, and 35% respectively). CD16/CD57 expression 
decreased in NK-CD56
dim
 and increased in NK-CD56
bright
 cells over the three studied stages. 
CONCLUSION: Our results show changes in NK cells characteristics during tumor 
development: reversal of NK-CD56
dim
/NK-CD56
bright
 distribution and modification of CD16/CD57 
expression. Both types of changes can concur in reducing the efficiency of NK cell activity in 
patients with progressive tumors. 
 
 
 
 
 
Introduction 
 
NK cells are characterized as large granular 
lymphocytes with the CD3
-
CD16
+
CD56
+
 phenotype [1-
3] and antitumor cytotoxic activity [4-7]. Other 
molecules associated with these cells have been 
described, such as adhesion molecule CD57, 
cytotoxicity receptors KIR (CD158), LIR (CD85), 
NKG2 (CD94, CD315) and NKP (CD335, CD336) [8-
11]. During the last decade, two distinct 
subpopulations of NK cells were characterized as 
having primary phenotypic expression associated with 
a specific function: NK-CD56
dim
 (CD56
dim/neg
, CD56
low
) 
and NK-CD56
bright
 (CD56
high
) [12-14]. NK-CD56
dim
 
cells comprise the majority of peripheral blood and 
spleen NK cells (> 95%), they have CD16
+/-
CD57
-
KIR
+
NKP
+
 phenotype and are involved in antitumor 
cytotoxicity [15, 16]. NK-CD56
bright
 cells represent 
approximately 10% of all NK cells, are mainly located 
in the lymph nodes and tonsils, express predominantly 
CD16
+/-
CD57
-
KIR
-
 phenotype, lacking cytotoxicity 
receptors but are involved in the active secretion of 
cytokines [17-19]. 
The particular distribution of NK 
subpopulations can be significant and suggestive 
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when evaluating their cytotoxic potency as vigorous 
antitumor cellular immune response players. Some 
deficiencies in the function of tumor-infiltrating NK 
cells have been observed [20-22], showing that the 
tumor microenvironment may play an important role in 
the development of NK cytotoxicity. However, a 
relationship between the intratumoral NK cell 
functions and NK-CD56
dim
/ NK-CD56
bright
 subsets 
could not be clearly established. In contrast, 
significant features were recently discovered by 
investigating the distribution of NK blood subsets. The 
reported results indicate that predominance of 
peripheral CD56
dim
CD16
+
KIR
+
 NK cells constitutes an 
end result of the recruitment of NK-CD56
bright
CD16
-
KIR
-
 in the local immune response [23]. This 
phenomenon seems to be facilitated by chemokines 
[24] and upon IL-2, IL-12 or IL-15 stimulation [25]. 
Although some particular aspects of NK 
subpopulations distribution in the peripheral blood 
have been already observed in viral diseases [26, 27], 
pregnancy [28, 29] and even in autoimmune diseases 
[30], data regarding their value in the diagnosis of 
cancer are scarce. 
Based on our preliminary studies [31], we now 
attempt to compare different aspects of the phenotype 
and peripheral NK cell subpopulations along the three 
progressive stages of tumor development: primary 
tumor (PT), lymph node invasion (LNI), metastases 
(Mt). We consider that, among other features, the 
diagnosis and monitoring of tumor development 
depend on the assessment of changes in the 
distribution of NK cells. 
 
 
Materials and Methods 
 
Patients 
Whole peripheral blood samples were 
collected from 36 cancer patients (24 patients with PT, 
6 patients with LNI and 6 patients with Mt). All 
subjects gave informed consent before their inclusion 
in the study. 
PTs were 10 retroperitoneal, 2 kidney, 2 
bladder, 4 colons, 2 gastric, 2 breasts, 1 ovarian, 1 
pelvis. There were 11 man and 13 women, average 
age 62. The patients with LNI had either 
osteosarcoma, breast, squama cellular, colon, renal 
and perineal tumor. There were 4 man and 2 women, 
average age 63. Mt came from 3 colorectal, 1 gastric, 
1 breast and 1 retroperitoneal carcinoma. There were 
4 man and 2 women, average age 65.  
No patient supported immunomodulatory 
treatment at the moment of testing. Blood samples 
from 10 healthy donors served as controls. 
The study was approved by the institution 
ethics committee. 
Lymphocyte immunophenotyping 
All patients and control subjects were tested 
for lymphocyte populations (T, B and NK cells) by flow 
cytometry immunophenotyping at FACSCalibur 
cytometer (BD Biosciences, San Jose, CA, USA), 
using 4-colour automatic methodology. The blood was 
processed with MultiTest IMK Kit (BD Biosciences) 
according to manufacturer's instructions. 
Data acquisition was performed using BD MultiSet 
software. 
 
Characterization of NK cells 
Given that MultiTest immunophenotyping kit 
evaluates only CD16
+
 NK cells subset, we performed 
an additional analysis of NK cell phenotype by 
assessing CD16/CD57 expression and 
CD56
dim
/CD56
bright
 subpopulations. The analysis was 
performed in 8 patients with PT and all patients with 
LNI and Mt. The peripheral blood samples were 
labeled with CD3PerCP, CD56APC, CD16PE and 
CD57FITC (BD Biosciences) and then phenotyped at 
FACSCalibur cytometer by the 4-color manual 
method, using BD CellQuest software for data 
acquisition (Figure 1). All monoclonal antibodies were 
used according to manufacturer's instructions as 
previously described [32]. 
 
 
Figure 1: Flow cytometric dot plot analysis of NK cell subsets.The 
determination with BD FACSCalibur cytometer by manual 4-color 
method, data acquisition with BD CellQuest software. a: CD3
-
 cells 
of total lymphocytes, b: CD3
-
CD56
+
 cells (NK cells), c: NK-CD56
dim
 
and NK-CD56
bright
 subpopulations in CD3
-
CD56
+
 cells, d: CD16
+
 
phenotype in NK cell subpopulations, e: CD57
+
 phenotype in the NK 
cell subpopulations  
 
Statistical analysis 
The results are presented as the mean ± 
standard deviation of cell percentages. 
The T, B and NK cells were measured as a 
percentage of total lymphocytes. Normal ranges are 
5
th
 to 95
th
 percentile, as stated in Table 1.  
NK subpopulations and cell phenotypes were 
calculated as percentages of total CD56
+
 cells. 
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Graphs and t-test were performed using Microsoft 
Excel software. 
 
 
Results 
 
Lymphocyte immunophenotyping  
The populations of peripheral blood 
lymphocytes revealed some differences in the 
distribution of cells between the three stages of tumor 
development (Table I). Thus, CD4
+
 T-cells and B cells 
were higher in patients with PTs compared to the level 
observed in patients with Mt. CD8
+
 T cells were higher 
in patients with Mt, compared to the patients with PT. 
In addition, T-CD4+: T-CD8+ ratio was lower in LNI 
and Mt patients than in patients with PTs. 
Table 1: Lymphocyte percentages in peripheral blood of tested 
subjects 
Cells Controls PT patients 
LNI 
patients 
Mt patients 
Normal 
range 
T-CD3
+
 69 ± 6 67 ± 13 78 ± 11 70 ± 12 56 – 86 
T-CD4
+
 41 ± 5 40 ± 11 40 ± 9 34 ± 6
****
 33 – 57 
T-CD8
+
 28 ± 7 26 ± 14 36 ± 9 36 ± 12
****
 13 – 39 
T-CD4+:T-CD8+ ratio 1.6 ± 0.4 2.0 ± 1.0 1.2 ± 0.5
***
 1.0 ± 0.3
*
 1.5 – 2.5 
B 13 ± 3 12 ± 5 6 ± 3
**
 9 ± 3
***
 6 – 22 
NK 16 ± 5 19 ± 14 16 ± 13 21 ± 11 5 – 25 
 a 
5
th
 to 95
th
 percentile, as presented by MultiTest IMK Kit manufacturer; 
* 
p < 0.001 
compared to PT patients; 
 ** 
p < 0.01 compared to PT patients; 
*** 
p < 0.02 compared to PT 
patients; 
 **** 
p < 0.05 compared to PT patients. 
 
The distribution of NK cells did not show any 
significant variation between control subjects and 
patients with PTs. Also, no significant imbalance has 
been observed during the stages of tumor 
development in terms of percentage of NK cells. 
 
Characterization of NK cells 
 a. CD16/CD57 expression  
Total NK cells (CD56
+
) were further examined 
to determine CD16
+
 or CD57
+
 phenotype (single-
positive cells) and CD16
+
CD57
+
 phenotype (double-
positive cells). The results are shown in Table 2.  
Irrespective of CD16
+
 or CD57
+
 phenotype, 
the percentages of single- or double-positive cells 
were the lowest in patients with LNI as compared to 
controls or PT and Mt patients. As considering the 
three tumor development stages, the percentages of 
single- or double-positive cells were significantly 
higher in patients with PT, with no significant 
difference when comparing to controls. 
Table 2: NK cell phenotypes during tumor development stages 
 
NK cell phenotypes (% cells) 
CD56
+ a
 CD56
+
CD16
+ b
 CD56
+
CD57
+ b
 CD56
+
CD57
+
CD16
+
 
b
 
Controls 15 ± 6 93 ± 5 53 ± 13 52 ± 12 
PT patients  16 ± 12 86 ± 11 71 ± 17 65 ± 19 
LNI patients  10 ± 4 39 ± 28
*
 36 ± 18
**
 20 ± 18
*
 
Mt patients 26 ± 10 51 ± 17
**
 64 ± 12
***
 49 ± 18 
 a 
Percentage in all lymphocytes; 
b
 Percentage in CD56
+
 cells; 
*
 p < 0.001 compared to PT 
patients and controls; 
 **
 p < 0.01 compared to PT patients; 
***
 p < 0.05 compared to PT 
patients. 
b. CD56
dim
/CD56
bright
 subpopulations 
During the stages of tumor development, the 
distribution of NK-CD56
dim
/ NK-CD56
bright
 
subpopulations changed gradually (Figure 2). The 
patients with PT showed a similar distribution with the 
control subjects, i.e. NK-CD56
dim
 was the predominant 
subpopulation (93%). The percentage of NK-CD56
bright
 
subpopulation gradually increased from 7% in patients 
with PT to 13% in patients with LNI and 65% in 
patients with Mt (p <0.001), while NK-CD56
dim
 
subpopulation was decreasing. 
 
Figure 2: Changes in the distribution of NK-CD56
dim
/ NK-CD56
bright
 
subpopulations according to the period of tumor development 
 
NK-CD56
dim
/ NK-CD56
bright
 subpopulations 
showed similar variation as above in terms of 
CD16/CD57 phenotypes (Figure 3). In NK-CD56
dim
 
subpopulation, CD16
+
/CD57
+
 expression 
progressively decreased as follows: CD16
+ 
cells from 
89 ± 12% in PT patients to 11 ± 9% in Mt patients; 
CD57
+ 
cells from 73 ± 16 % in PT patients to 10 ± 6% 
in Mt patients; CD16
+
CD57
+
 cells from 68 ± 19% in PT 
patients to 7 ± 8% in Mt patients (Figure 3a).  
In NK-CD56
bright
 subpopulation, the 
CD16
+
/CD57
+
 expression progressively increased as 
follows: CD16
+ 
cells from 40 ± 33% in PT patients to 
91 ± 8% in Mt patients; CD57
+ 
cells from 28 ± 30% in 
PT patients to 71 ± 20% in Mt patients; CD16
+
CD57
+
 
cells from 28 ± 30% in PT patients to 70 ± 20% in Mt 
patients (Figure 3b). 
  
Figure 3: CD16/CD57 phenotypes in NK subpopulations during 
tumor stages. a: Changes in the phenotype of NK-CD56
dim
 
subpopulation, b: Changes in the phenotype of an NK-CD56
bright
 
subpopulation  
 
It must be emphasized that the values are not 
statistically significant because the three groups did 
not include the same patients. However, they could 
highlight a possible trend in expression of CD16/CD57 
markers along the evolutionary phases of the tumor.  
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Discussion 
 
We have focused on assessing the NK cell 
population in terms of its representation during the 
progressive stages of malignancy, from primary 
tumors, lymph nodes involvement to distant sites 
metastasis (PT, LNI, Mt). It is known that NK cells are 
actively involved in the anti-tumoral response, hence, 
we wanted to evaluate NK cell phenotype and their 
subpopulations distribution in the peripheral blood as 
possible indicators of tumor development to more 
advanced stages. At the same time, evaluating the 
specific phenotype in relation to tumor evolution, new 
markers indicating antitumor cellular cytotoxicity could 
be revealed. We have purposely chosen different solid 
cancers to highlight that stages of tumor development 
can have common immune-related mechanisms, 
possibly sustained by a clear anti-tumoral cell like NK 
population. 
The above-mentioned stages of tumor 
progression we considered were mainly clinical, 
concerning that they were diagnosed by standard 
clinical/paraclinical methods. Therefore, an auxiliary 
method as the determination of NK cells supplies 
additional information, indicating how the tumor 
growth and evolution affect these cells. This could be 
important since the non-surgical anti-tumor therapy 
may target for specific NK activity improvement [22].  
The percentages of peripheral blood NK cells 
varied slightly in patients at different stages of tumor 
development. In spite of this minor variation, other 
data can be provided by analyzing the expression of 
CD16 and CD57 molecules or distribution of NK-
CD56
dim
/ NK-CD56
bright
 subsets. Although functional 
differences between the two NK subpopulations are 
well known [15, 17], relatively little evidence was 
provided about their participation in specific antitumor 
response and their possible assessment during tumor 
development.  
We also have observed two changes in NK 
subpopulațions during tumor evolution: a downward 
trend in the share of NK-CD56
dim
 subpopulation and 
on the other hand a progressive increase of NK-
CD56
bright
 subpopulation. Taking into account that NK-
CD56
dim
 cells exert largely cytotoxic actions, we 
assume that tumor progression could be favored by 
the decrease of this subpopulation. Given that the 
increased NK-CD56
bright
 cells develop regulatory 
activities, it can be concluded that they are not very 
effective in the recruitment of other active cytotoxic 
cells, such as CD8
+
 T cells, which are essential to the 
eradication of metastatic tumors [33]. Even if we found 
significantly increased peripheral blood CD8
+
 T cells 
in patients with Mt compared to PT patients, it is 
doubtful whether these cytotoxic cells are capable of 
working effectively. For this reason, we tend to 
assume that changing the  
NK-CD56
dim
/NK-CD56
bright
 balance in favor of NK-
CD56
bright
 cells may represent probably a warning sign 
for tumor escape. 
Examining the CD16/CD57 phenotype, we 
observed that the percentages of positive NK cells 
were significantly lower in patients with LNI compared 
to the levels observed in PT or Mt patients. Knowing 
that both CD16 and CD57 molecules are involved in 
intercellular interactions, we can emphasize that this 
decrease could be an issue in NK cell adhesion during 
tumor growth, especially in the lymph node invasion 
process, which seems to be a critical moment. This 
phenomenon may be exacerbated by the lower NK-
CD56
dim
 subpopulation with decreased CD16/CD57 
expression and cannot be corrected by the increase of 
NK-CD56
bright
 subset. Thus, such a hypothetical 
replacement of a cytotoxic subpopulation (NK-
CD56
dim
) with a regulatory subpopulation (NK-
CD56
bright
) cannot be beneficial in terms of cytotoxicity 
efficiency and anti-tumoral effect [5]. 
Our presented results pinpoint an ineffective 
change of the peripheral blood NK cells during 
tumorigenesis and tumor dynamics: gradual decrease 
of the NK-CD56
dim
 and increase of the NK-CD56
bright
 
subpopulations. This could favor tumor invasion in the 
lymph nodes, ending with a reversal of the NK-
CD56
dim
/ NK-CD56
bright
 distribution in the course of 
metastasis process. Changing in CD16/CD57 co-
expression on NK cells can cause difficulties in 
efficient cytotoxicity by reducing the intercellular 
contact, a critical step in developing an anti-tumoral 
effect. Each of these changes contributes to the 
ineffectiveness of NK cells and hence tumor 
progression. These features can be sensed indirectly 
by phenotypic characterization of NK cells and their 
subpopulations and could be cellular markers of poor 
clinical outcome in solid tumors. 
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